10. The composition of claim 1, wherein the polypeptide comprises a substitution of an N-terminal Cys compared to the corresponding wild-type non-lipidated ORF2086 polypeptide.

11. A composition comprising a non-pyruvylated non-lipidated ORF2086 polypeptide obtainable by a process comprising expressing a nucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:12, wherein the cysteine at position 1 is deleted, wherein the nucleotide sequence is operatively linked to an expression system that is capable of being expressed in a bacterial cell.

12. The composition of claim 11, wherein the bacterial cell is *E. coli*.

13. The composition according to any of claims 1-12, wherein the composition is immunogenic.

14. The composition of claim 1, further comprising an ORF2086 subfamily A polypeptide from serogroup B *Neisseria meningitidis*.

15. The composition according to any of claims 1-12, wherein the composition elicits a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B *Neisseria meningitidis*.

~~16. Use of an effective amount of an isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 44 and SEQ ID NO: 49, or a combination thereof, in the manufacture of a medicament for eliciting bactericidal antibodies specific to an ORF2086 subfamily B serogroup B *Neisseria meningitidis*.~~

~~17. A method for producing a polypeptide comprising expressing in a bacterial cell a polypeptide, which comprises a sequence having greater than 90% identity to SEQ ID NO:21, said sequence comprising at least one domain selected from the group consisting of amino acids 13-18 of SEQ ID NO: 21, amino acids 21-34 of SEQ ID NO: 21, and amino acids 70-80 of SEQ ID NO: 21, or a combination thereof, wherein the sequence lacks an N-terminal cysteine; and purifying the polypeptide.~~

18. The method of claim 17, wherein the sequence further comprises at least one domain selected from the group consisting of amino acids 96-116 of SEQ ID NO: 21, amino acids 158-170 of SEQ ID NO: 21, amino acids 172-185 of SEQ ID NO: 21, amino acids 187-199 of SEQ ID NO: 21, amino acids 213-224 of SEQ ID NO: 21, amino acids 226-237 of SEQ ID NO: 21, amino acids 239-248 of SEQ ID NO: 21, or a combination thereof.

19. The method of claim 17, wherein the bacterial cell is *E. coli*.

20. An isolated polypeptide produced by a process comprising the method of claim 17.

21. An immunogenic composition produced by a process comprising the method of claim 17.

22. An immunogenic composition comprising an ORF2086 subfamily B polypeptide from serogroup B *Neisseria meningitidis*, wherein the polypeptide is a non-pyruvylated non-lipidated B44.

23. The composition of claim 22, further comprising a second ORF2086 subfamily B polypeptide from serogroup B *Neisseria meningitidis*, wherein the second polypeptide is a non-pyruvylated non-lipidated B09.

24. The composition of claim 22, wherein said composition comprises no more than 3 ORF2086 subfamily B polypeptides.

25. The composition of claim 22, wherein said composition comprises no more than 2 ORF2086 subfamily B polypeptides.

26. The composition of claim 22, wherein said composition further comprises a ORF2086 subfamily A polypeptide.

27. The composition of claim 26, wherein said composition comprises an A05 subfamily A polypeptide.